Chemicals and Drugs Commons^™

Changes In Anticoagulant Utilization Among United States Nursing Home Residents With Atrial Fibrillation From 2011 To 2016, Matthew Alcusky, David D. Mcmanus, Anne L. Hume, Marc Fisher, Jennifer Tjia, Kate L. Lapane

Jennifer Tjia

Background: Nursing home residents with atrial fibrillation are at high risk for ischemic stroke and bleeding events. The most recent national estimate (2004) indicated less than one third of this high-risk population was anticoagulated. Whether direct-acting oral anticoagulant ( DOAC ) use has disseminated into nursing homes and increased anticoagulant use is unknown.

Methods and Results: A repeated cross-sectional design was used to estimate the point prevalence of oral anticoagulant use on July 1 and December 31 of calendar years 2011 to 2016 among Medicare fee-for-service beneficiaries with atrial fibrillation residing in long-stay nursing homes. Nursing home residence was determined …

A Meta-Analysis Of Incidence And Risk Factors Of Trastuzumab-Induced Cardiotoxicity In Breast Cancer, Zeeshan Ali Jawa, Ruth M. Perez, Lydia Garlie, Maharaj Singh, Rubina Qamar, Bijoy K. Khandheria, Arshad Jahangir, Yang Shi

Maharaj Singh

Background: A monoclonal antibody, trastuzumab targets the human epidermal growth factor receptor 2 (HER2) oncogene that is overexpressed in 25–30% of breast cancers. In combination with first-line therapy, trastuzumab resulted in significant improvement in survival outcomes for those with HER2-positive metastatic breast cancer. Due to its improvement in outcome and prolonged survival, trastuzumab has been established as standard of care in both adjuvant and metastatic settings. However, along with common adverse events, trastuzumab has been found to be associated with cardiotoxicity. An estimated 1–4% of patients treated with trastuzumab will develop heart failure and ~10% of patients will experience a …

A Meta-Analysis Of Incidence And Risk Factors Of Trastuzumab-Induced Cardiotoxicity In Breast Cancer, Zeeshan Ali Jawa, Ruth Perez, Lydia Garlie, Maharaj Singh, Rubina Qamar, Bijoy Khandheria, Arshad Jahangir, Yang Shi

Arshad Jahangir, MD

Background: A monoclonal antibody, trastuzumab targets the human epidermal growth factor receptor 2 (HER2) oncogene that is overexpressed in 25–30% of breast cancers. In combination with first-line therapy, trastuzumab resulted in significant improvement in survival outcomes for those with HER2-positive metastatic breast cancer. Due to its improvement in outcome and prolonged survival, trastuzumab has been established as standard of care in both adjuvant and metastatic settings. However, along with common adverse events, trastuzumab has been found to be associated with cardiotoxicity. An estimated 1–4% of patients treated with trastuzumab will develop heart failure and ~10% of patients will experience a …

Health Action Process Approach: Application To Medication Adherence In Cardiac Rehabilitation Patients, Anna Greer, Kerry Milner, Richard Marcello, Katie Mazin

Anna E. Greer

The purpose of this study was to examine the relationship between Health Action Process Approach (HAPA) post-intentional constructs (maintenance self-efficacy, recovery self-efficacy, action planning, coping planning) and medication adherence among phase II cardiac rehabilitation (CR) patients. Research Method: Purposive sampling was used to recruit 91 phase II CR patients age 50 years and over. All respondents completed paper and pencil questionnaire examining HAPA post-intentional constructs (action planning, coping planning, maintenance self-efficacy, recovery self-efficacy), medication adherence, and demographic characteristics. Validity and reliability were confirmed for all scales included in the questionnaire. Descriptive statistics were used to describe respondents’ characteristics. Bivariate statistics …

Atrial Fibrillation--Advances In Drug Therapy, Sudip Nanda, Sultan Siddique, Matthew Martinez, Shree Sharma, Nainesh Patel, Santo Longo

Nainesh C Patel MD

No abstract provided.

Comparison Of Insulin Infusion Protocols Targeting 110-140 Mg/Dl In Patients After Cardiac Surgery., Vasudev Magaji, Shriddha Nayak, Amy Donihi, Lauren Willard, Srinivasa Jampana, Parachur Nivedita, Raymond Eder, Jann Johnston, Mary Korytkowski

Vasudev G Magaji MD, MS

BACKGROUND: Continuous intravenous insulin infusion (CII) following coronary artery bypass graft (CABG) surgery reduces postoperative complications and hospitalization duration. Because of limited data evaluating outcomes of CII with revised glycemic targets (110-140 mg/dL) in cardiac surgery, this study compared efficacy and safety of two different CII protocols having revised targets. SUBJECTS AND METHODS: This is a retrospective study comparing two different protocols between August 2009 and March 2010. Protocol 1 consists of four algorithms, and Protocol 2 is a table to adjust CII. Blood glucose (BG) and CII rates were recorded for 48 h postoperatively or CII discontinuation. Efficacy was …

Aldosterone Antagonism With Eplerenone Does Not Adversely Affect Plasma Glucose Levels In Patients With Diabetes Mellitus: Findings From A Post Hoc Analysis Of The Ephesus Trial, Prakash Deedwania Md, Bertram Pitt, Ravi V. Desai Md, Marjan Mujib Md, Mph, Inmaculada B. Aban Phd, J Vincent, E Turgonyi, Ali Ahmed Md, Mph

Ravi V Desai MD

No abstract provided.

Venous Thromboembolism In Patients With Heart Failure: In-Hospital And Chronic Use Of Anti-Coagulants For Prevention, Nasir Shariff, Abdul Aleem, Vadim Levin, Sudip Nanda, Matthew Martinez, Stacey Smith, Ronald Freudenberger

Vadim A Levin MD

No abstract provided.

Ranolazine—Treatment Of Ventricular Tachycardia And Symptomatic Ventricular Premature Beats In Ischemic Cardiomyopathy, Sudip Nanda, Vadim Levin, Matthew Martinez, Ronald Freudenberger

Vadim A Levin MD

No abstract provided.

Novel Oral Anticoagulants For Stroke Prevention In Patients With Atrial Fibrillation: Dawn Of A New Era, Tahmeed Contractor, Vadim Levin, Matthew Martinez, Francis Marchinski

Vadim A Levin MD

No abstract provided.

Warfarin Use And Outcomes In Patients With Advanced Chronic Systolic Heart Failure Without Atrial Fibrillation, Prior Thromboembolic Events, Or Prosthetic Valves, Marjan Mujib, Abu-Ahmed Rahman, Ravi Desai, Mustafa Ahmed, Margaret Feller, Inmaculada Aban, Tomas Love, Michel White, Prakash Deedwania, Wilbert Aronow, Gregg Fonarow, Ali Ahmed

Ravi V Desai MD

No abstract provided.

Influence Of Co-Existing Atrial Fibrillation On The Efficacy Of Atorvastatin Treatment In Patients With Dilated Cardiomyopathy: A Pilot Study, Agata Bielecka-Dabrowa, Jan Goch, Jacek Rysz, Marek Maciejewski, Ravi Desai, Wilbert Aronow

Ravi V Desai MD

No abstract provided.

Relationship Between Left And Right Ventricular Ejection Fractions In Chronic Advanced Systolic Heart Failure: Insights From The Best Trial, Ravi Desai, Philippe Meyer, Mustafa Ahmed, Marjan Mujib, Chris Adamopoulos, Michel White, Inmaculada Aban, Ami Iskandrian, Ali Ahmed

Ravi V Desai MD

No abstract provided.

Effect Of Warfarin On Outcomes In Septuagenarian Patients With Atrial Fibrillation, Brita Roy, Ravi Desai, Marjan Mujib, Andrew Epstein, Yan Zhang, Jason Guichard, Linda Jones, Margaret Feller, Mustafa Ahmed, Inmaculada Aban, Thomas Love, Michel White, Wilbert Aronow, Ali Ahmed

Ravi V Desai MD

No abstract provided.

Cost-Effectiveness Of Lowering Blood Pressure With A Fixed Combination Of Perindopril And Indapamide In Type 2 Diabetes Mellitus: An Advance Trial-Based Analysis, Paul Glasziou, Philip Clarke, Jan Alexander, Mohana Rajmokan, Elaine Beller, Mark Woodward, John Chalmers, Neil Poulter, Anushka Patel

Elaine Beller

Objective: To determine the cost-effectiveness of routine administration, irrespective of blood pressure (BP), of a fixed-dose combination of perindopril and indapamide to patients with type 2 diabetes mellitus.

Design, setting and participants: Prospective cost-effectiveness analysis within the Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation (ADVANCE) trial, an international, multicentre, randomised controlled trial of 11 140 participants with type 2 diabetes randomly allocated to receive perindopril plus indapamide (4mg-1.25mg/day) or placebo.

Main outcome measures: Health-related quality-of-life measured by the EuroQol-5D, resource utilisation, and cost-effectiveness (cost per death averted at 4.3 years' average follow-up, and …